Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic fecal microbiota transplant
- Development stage
- Unknown
- Lead developer
- Lawson Health Research Institute
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Nasoduodenal
01
Overview
Allogeneic fecal microbiota transplant (FMT) is a microbial therapy involving the transfer of a complete gut microbiome from healthy, lean donors to patients with metabolic disorders. Developed by the Lawson Health Research Institute in partnership with the London Health Sciences Centre and Western University, the therapy is specifically being evaluated for non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome. The mechanism of action involves the restoration of a healthy microbial ecosystem in the recipient's gut, which is intended to reduce intestinal permeability (leaky gut) and subsequent systemic inflammation. In clinical study protocols, the processed fecal material is administered to the distal duodenum via endoscopy. Although a pilot trial demonstrated a significant reduction in small intestinal permeability in certain patients, it did not meet primary endpoints for insulin resistance or liver fat reduction.
- Other names
- allogeneic FMTfecal microbiota transplantation
Beyond the preview
Go deeper on allogeneic fecal microbiota transplant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic fecal microbiota transplant.